![Chris Mason](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenienza dei contatti di primo grado di Chris Mason
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Proteus RM LLC (Venture Capital)
![]() Proteus RM LLC (Venture Capital) Investment ManagersFinance Proteus RM LLC (Venture Capital) (Proteus RM) is a venture capital subsidiary of Proteus RM LLC founded in 2006 by Gregory A. Bonfiglio. The firm is headquartered in Portola Valley, California.
2
| Subsidiary | Investment Managers | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Chris Mason tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
StemCyte, Inc.
![]() StemCyte, Inc. BiotechnologyHealth Technology StemCyte, Inc. operates as a biotechnology company that collects, banks and distributes cord blood stem cell transfusion units. It focuses on stem cell transplantation, therapy, applications, diagnostics, and genomic research. The firm uses insulated containers to keep your baby's cord blood cool throughout transport. The company was founded by Denis Rodgerson and Robert Chow in 1997 and is headquartered in Covina, CA. | Biotechnology | Director/Board Member | |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | Pharmaceuticals: Major | Director/Board Member | |
Michigan State University | College/University | Undergraduate Degree | |
Morrison & Foerster LLP
![]() Morrison & Foerster LLP Miscellaneous Commercial ServicesCommercial Services Morrison & Foerster LLP is a law firm that provides legal services on various industries, which include: litigation, financial services, intellectual property and technology, and transactional work, such as corporate, capital markets and real estate finance representations. The company was founded in 1883 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
International Society for Cellular Therapy
![]() International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Anthem Venture Management LLC
![]() Anthem Venture Management LLC Investment ManagersFinance Anthem Venture Management LLC (Anthem Venture Management) is a venture capital firm founded in 2000. The firm is headquartered in Santa Monica, California. | Investment Managers | Corporate Officer/Principal | |
The International Society for Stem Cell Research | Corporate Officer/Principal | ||
VISTAGEN THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Proteus LLC
![]() Proteus LLC Investment ManagersFinance Part of Keystone International Holdings LLC, Proteus LLC is a company that offers a complete accredited investor solution for investing in alternative assets. The company is based in Indianapolis, IN. The company provides opportunities for sophisticated investors, advisors, institutions, managers, and sponsors. Proteus offers a world-class analytical engine and private investing, allowing for smarter investing and better control. The company was founded by Gregory A. Bonfiglio. Gregory A. Bonfiglio has been the CEO since incorporation. | Investment Managers | Chief Executive Officer | |
Centre For Commercialization of Regenerative Medicine
![]() Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | Biotechnology | Chairman | |
HEALIOS K.K. | Pharmaceuticals: Major | Director/Board Member | |
The University of Michigan Law School | College/University | Graduate Degree | |
ImmuneBridge, Inc.
![]() ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
Stati Uniti | 13 |
Canada | 3 |
Giappone | 2 |
Settori
Health Technology | 8 |
Consumer Services | 3 |
Commercial Services | 3 |
Finance | 3 |
Technology Services | 2 |
Posizioni
Director/Board Member | 7 |
Corporate Officer/Principal | 4 |
Founder | 2 |
Private Equity Investor | 2 |
Independent Dir/Board Member | 2 |
Contatti più connessi
Insiders | |
---|---|
Gregory Bonfiglio | 16 |
Jeff Karan | 1 |
- Borsa valori
- Insiders
- Chris Mason
- Connessioni Società